PMID- 28460640
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20181113
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 18
IP  - 1
DP  - 2017 May 1
TI  - Physical performance and protein-energy wasting in patients treated with 
      nocturnal haemodialysis compared to conventional haemodialysis: protocol of the 
      DiapriFIT study.
PG  - 144
LID - 10.1186/s12882-017-0562-1 [doi]
LID - 144
AB  - BACKGROUND: Poor physical performance and protein-energy wasting (PEW) are health 
      issues of major concern in haemodialysis patients. The conventional haemodialysis 
      (CHD) regime, three times per week 3-5 h, is subject of discussion because of 
      high morbidity and mortality rates. When patients switch from CHD to longer 
      dialysis sessions, i.e. nocturnal haemodialysis (NHD), improvement in protein 
      intake and increase in body weight is seen. However, it is unclear whether 
      physical performance and more important aspects of PEW, such as body composition, 
      improve as well. Therefore, the aim of this study is to investigate whether 
      physical performance improves and PEW decreases, when patients switch from CHD to 
      NHD. A second aim is to assess the influence of NHD on the biomarkers fibroblast 
      growth factor-23 and sclerostin which are thought to be associated with 
      malnutrition and mortality in patients on haemodialysis. METHODS: This study is a 
      prospective multicentre cohort study with an inclusion aim of 50 patients: 25 
      patients in a control group (three times per week, 3-5 h CHD) and 25 patients in 
      a nocturnal group (three times per week, 7-9 h NHD). Primary outcome is change in 
      physical performance, measured by the Short Physical Performance Battery. 
      Additional measurements are a 6-min walk test, handgrip strength, a physical 
      activity questionnaire and physical activity monitoring. The secondary outcome of 
      the study is PEW, which will be evaluated by body weight, dual-energy X-ray 
      absorptiometry, bio-electrical impedance spectroscopy, mid-upper arm muscle 
      circumference, subjective global assessment, visual analogue scale for appetite 
      and dietary records. Laboratory measurements including fibroblast growth 
      factor-23 and sclerostin, and quality of life assessed with the Kidney Disease 
      Quality of Life-Short Form are also studied. In every patient, four repeated 
      measurements will be performed during one year of follow-up. DISCUSSION: This 
      study will investigate whether physical performance improves and PEW decreases 
      when patients switch from CHD to NHD, compared to a control group who continue 
      treatment with CHD. Strengths of this study are the comparison with a 
      conventional haemodialysis cohort, and the broad variety of objective 
      measurements combined with patient-reported outcomes of physical performance and 
      PEW. TRIAL REGISTRATION: NTR4715 , Netherlands Trial Register. Registered 30 July 
      2014.
FAU - Dam, Manouk
AU  - Dam M
AUID- ORCID: 0000-0001-5648-6888
AD  - VU University Medical Centre, department of Nutrition and Dietetics, Boelelaan 
      1117, 1081HV, Amsterdam, The Netherlands. m.dam2@vumc.nl.
FAU - Neelemaat, Floor
AU  - Neelemaat F
AD  - VU University Medical Centre, department of Nutrition and Dietetics, Boelelaan 
      1117, 1081HV, Amsterdam, The Netherlands.
FAU - Struijk-Wielinga, Trudeke
AU  - Struijk-Wielinga T
AD  - VU University Medical Centre, department of Nutrition and Dietetics, Boelelaan 
      1117, 1081HV, Amsterdam, The Netherlands.
FAU - Weijs, Peter J
AU  - Weijs PJ
AD  - VU University Medical Centre, department of Nutrition and Dietetics, Boelelaan 
      1117, 1081HV, Amsterdam, The Netherlands.
FAU - van Jaarsveld, Brigit C
AU  - van Jaarsveld BC
AD  - VU University Medical Centre, department of Nephrology, Boelelaan 1117, 1081HV, 
      Amsterdam, The Netherlands.
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20170501
PL  - England
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Body Weight
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/*complications/*rehabilitation
MH  - Male
MH  - Middle Aged
MH  - Netherlands
MH  - *Physical Fitness
MH  - Protein-Energy Malnutrition/*etiology/*prevention & control
MH  - Renal Dialysis/*adverse effects/*methods
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC5412044
OTO - NOTNLM
OT  - Fibroblast growth factor-23
OT  - Nocturnal haemodialysis
OT  - Physical performance
OT  - Protein-energy wasting
OT  - Sclerostin
EDAT- 2017/05/04 06:00
MHDA- 2018/02/27 06:00
PMCR- 2017/05/01
CRDT- 2017/05/03 06:00
PHST- 2016/04/29 00:00 [received]
PHST- 2017/04/20 00:00 [accepted]
PHST- 2017/05/03 06:00 [entrez]
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
PHST- 2017/05/01 00:00 [pmc-release]
AID - 10.1186/s12882-017-0562-1 [pii]
AID - 562 [pii]
AID - 10.1186/s12882-017-0562-1 [doi]
PST - epublish
SO  - BMC Nephrol. 2017 May 1;18(1):144. doi: 10.1186/s12882-017-0562-1.